2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI)

Modify Date: 2024-01-06 13:14:15

2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI) Structure
2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI) structure
Common Name 2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI)
CAS Number 588674-64-0 Molecular Weight 319.278
Density 1.4±0.1 g/cm3 Boiling Point 345.9±42.0 °C at 760 mmHg
Molecular Formula C17H12F3NO2 Melting Point N/A
MSDS N/A Flash Point 163.0±27.9 °C

 Use of 2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI)


CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs)[1].

 Names

Name 3-Methyl-N-[4-(trifluoromethyl)phenyl]-1-benzofuran-2-carboxamide
Synonym More Synonyms

  Biological Activity

Description CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs)[1].
Related Catalog
Target

CCR6

In Vitro CCR6 antagonist 1 (compound 1b, 50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration[1]. CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1]. Cell Migration Assay [1] Cell Line: CCL20 (500 ng/mL)-induced CCR6+CD4+ T cell Concentration: 0.5, 5, 50 μM Incubation Time: 3 h Result: Inhibited CCL20-induced cell migration at 50 μM.
In Vivo CCR6 antagonist 1 (compound 1b, 1 mg/kg, s.c., twice daily for 3 days) alleviates TNBS-induced inflammatory responses in mice[1]. CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects in Zymosan-induced peritonitis mice[1]. Animal Model: Murine model of colitis (5 mg/mouse TNBS-induced)[1] Dosage: 1 mg/kg Administration: Subcutaneous injection (s.c.), twice daily for 3 days. Result: Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs. Animal Model: Zymosan-induced peritonitis mice[1] Dosage: 1 mg/kg Administration: Subcutaneous injection (s.c.), twice, before and after zymosan treatment Result: Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.
References

[1]. Maria Grazia Martina, et al. Discovery of small-molecules targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases. Eur J Med Chem. 2022 Aug 29;243:114703.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 345.9±42.0 °C at 760 mmHg
Molecular Formula C17H12F3NO2
Molecular Weight 319.278
Flash Point 163.0±27.9 °C
Exact Mass 319.082001
LogP 4.18
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.604

 Synonyms

2-Benzofurancarboxamide, 3-methyl-N-[4-(trifluoromethyl)phenyl]-
3-Methyl-N-[4-(trifluoromethyl)phenyl]-1-benzofuran-2-carboxamide
MFCD03943591
Top Suppliers:I want be here



Get all suppliers and price by the below link:

2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI) suppliers

2-Benzofurancarboxamide,3-methyl-N-[4-(trifluoromethyl)phenyl]-(9CI) price

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3